Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Go back to Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting| FATE THERAPEUTICS (NASDAQ: FATE) | Delayed: 2.06 +0.09 (4.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.97 | 52 Week High | $4.76 | |||
| Open | $2.00 | 52 Week Low | $1.46 | |||
| Day High | $2.16 | P/E | N/A | |||
| Day Low | $1.93 | EPS | $-1.91 | |||
| Volume | 4,698,730 | |||||
